DE69130262D1 - Isolierte virale proteine als cytokinantagonisten - Google Patents

Isolierte virale proteine als cytokinantagonisten

Info

Publication number
DE69130262D1
DE69130262D1 DE69130262T DE69130262T DE69130262D1 DE 69130262 D1 DE69130262 D1 DE 69130262D1 DE 69130262 T DE69130262 T DE 69130262T DE 69130262 T DE69130262 T DE 69130262T DE 69130262 D1 DE69130262 D1 DE 69130262D1
Authority
DE
Germany
Prior art keywords
isolated viral
viral proteins
cytokinantagonists
disclosed
cytokine antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69130262T
Other languages
English (en)
Other versions
DE69130262T2 (de
Inventor
Craig Smith
Raymond Goodwin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of DE69130262D1 publication Critical patent/DE69130262D1/de
Publication of DE69130262T2 publication Critical patent/DE69130262T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69130262T 1991-03-29 1991-03-29 Isolierte virale proteine als cytokinantagonisten Expired - Fee Related DE69130262T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1991/002207 WO1992017583A1 (en) 1991-03-29 1991-03-29 Isolated viral protein cytokine antagonists

Publications (2)

Publication Number Publication Date
DE69130262D1 true DE69130262D1 (de) 1998-10-29
DE69130262T2 DE69130262T2 (de) 1999-03-18

Family

ID=22225427

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69130262T Expired - Fee Related DE69130262T2 (de) 1991-03-29 1991-03-29 Isolierte virale proteine als cytokinantagonisten

Country Status (8)

Country Link
EP (1) EP0604418B1 (de)
JP (1) JPH06508502A (de)
AT (1) ATE171471T1 (de)
AU (1) AU646695B2 (de)
DE (1) DE69130262T2 (de)
DK (1) DK0604418T3 (de)
ES (1) ES2123515T3 (de)
WO (1) WO1992017583A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495515B1 (en) 1995-04-19 2002-12-17 Viron Therapeutics, Inc. Chemokine binding protein and methods of use therefor
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
EP0901379B1 (de) * 1996-05-22 2000-09-06 University Of Alberta Typ-2 chemokine-bindende proteine und verfahren zu deren verwendung
EP1034789A1 (de) * 1996-05-22 2000-09-13 University Of Alberta Typ-2 Chemokine-Bindende Proteine und Verfahren zu deren Verwendung
WO2000021981A2 (de) * 1998-10-09 2000-04-20 Bioserv Ag TNFα BINDENDE PEPTIDE UND IHRE ANWENDUNG FÜR DIE DETEKTION, INAKTIVIERUNG UND/ODER ENTFERNUNG VON TNFα AUS BIOLOGISCHEN FLÜSSIGKEITEN
US6589933B1 (en) 1999-04-02 2003-07-08 Viron Therapeutics, Inc. Myxoma chemokine binding protein
US6461837B1 (en) * 1999-11-30 2002-10-08 Novozymes Biotech, Inc. Methods for producing a polypeptide using a consensus translational initiator sequence
WO2002031115A2 (en) 2000-10-11 2002-04-18 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
ES2287192T3 (es) 2000-12-04 2007-12-16 Viron Therapeutics, Inc. Proteina inmunomoduladora derivada del virus de tumor del mono de yaba.
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
CN102961746B (zh) 2005-05-16 2016-06-15 艾伯维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
CA2911000A1 (en) 2006-04-05 2007-10-18 Min W. Wan Antibody purification
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2702077A2 (de) 2011-04-27 2014-03-05 AbbVie Inc. Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
EP3078675A1 (de) 2015-04-10 2016-10-12 Ares Trading S.A. Induktionsdosierschema zur behandlung von krankheiten die von tnf alpha verursacht sind
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
WO1991003553A1 (en) * 1989-09-05 1991-03-21 Immunex Corporation TUMOR NECROSIS FACTOR-α AND -β RECEPTORS

Also Published As

Publication number Publication date
DE69130262T2 (de) 1999-03-18
AU646695B2 (en) 1994-03-03
WO1992017583A1 (en) 1992-10-15
ATE171471T1 (de) 1998-10-15
EP0604418A1 (de) 1994-07-06
EP0604418B1 (de) 1998-09-23
DK0604418T3 (da) 1999-06-14
ES2123515T3 (es) 1999-01-16
JPH06508502A (ja) 1994-09-29
AU8656991A (en) 1992-11-02

Similar Documents

Publication Publication Date Title
DE69130262D1 (de) Isolierte virale proteine als cytokinantagonisten
MY102472A (en) Preparation of funtional human urokinase proteins.
ATE114169T1 (de) Morphogenetisches knochenprotein.
DK1149905T3 (da) Fremgangsmåder og præparat til polypeptidteknologi
DK0733067T3 (da) N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
YU19903A (sh) Novi receptor nukleinskih kiselina i polipeptida
BR9507657A (pt) Proteina isolada e purificada de papilomavirus recombinante capsideos particulas semelhantes a virus processos a virus processos para produzir a proteina para tratar ou prevenir a infecçao por papilomavirus para produzir uma proteina de capsideo de papilomavirus recombinante montada em um capsideo ou particula semelhante a virus e para induzir uma resposta imune em um animal vertebrado composiçoes farmacêuticas kit para a detecçao de papilomavirus ou anticorpos para papilomavirus e sistema sinte
ATE316982T1 (de) Mehrere zytokin-antikörper komplexen
EA200000311A1 (ru) Новый белок иммунной системы - кау
NO923953D0 (no) Peptider
TR199700610A3 (tr) Düsük molekül agirlikli çözünür, tümör nekroz faktörü tip-I ve tip-II proteinleri.
DE68925275D1 (de) Endotoxin-bindeprotein und dessen verwendung
DK11187A (da) Dna-sekvenser der koder for proteiner med husi-type i inhibitorers biologiske aktivitet, biotekniske fremgangsmaader til fremstilling af proteinerne o g farmaceutiske praeparater der indeholder dem
DK0480949T3 (da) Fremstilling af virus og oprensning af virale kappeproteiner til vaccineanvendelse
DK0538341T3 (da) EHV-4-gycoproteinvaccine.
DK0553294T3 (da) Fremstillingen af sammensætninger til behandlingen af celleproliferationssygdomme
DK383388D0 (da) 3-demethyl-4-fluor-mevalonsyrederivater, deres fremstilling, farmaceutiske praeparater deraf, deres anvendelse og mellemprodukter til deres fremstilling
WO2001040313A3 (en) Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
ATE189262T1 (de) Interferon-alpha/beta bindendes protein, seine herstellung und seine enthaltende pharmazeutische zusammensetzungen
FI950516A0 (fi) Interferoni-alfa/beta-sitojaproteiini, sen valmistus ja käyttö
CA2080355A1 (en) Isolated Viral Protein Cytokine Antagonists
SE9604439D0 (sv) New receptor
DE69836226D1 (de) Ifn rezeptor 1 bindende proteine, dafür kodierende dna und verfahren zur regulierung der zellulären antwort auf interferone
ATE102252T1 (de) Rekombinantes gefluegelpockenvirus, expressionsvektoren fuer heterologische proteine und davon derivierte gefluegelvakzine.
IT8921396A0 (it) Procedimento per la sintesi di peptidi preventivamente identificati come siti di interazione di proteine interagenti.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee